Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Conference Call and Webcast Information:
Eton Pharmaceuticals will host a conference call and webcast today at 4:30 p.m. ET (3:30 p.m. CT). To access the conference call, please dial 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 1891934. The webcast can be accessed under “Events & Presentations” in the Investors section of the Company’s website at https://ir.etonpharma.com. The webcast will be archived and made available for replay on the company’s website approximately two hours after the call and will be available for 30 days.
Earnings report for Eton
https://www.globenewswire.com/news-release/2021/03/16/2194071/0/en/Eton-Pharmaceuticals-Announces-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html
Brent up 1.7% on opening https://m.uk.investing.com/commodities/brent-oil
So it starts on the 22nd to the 25th
CHMP meeting dates isn’t the end of the month https://www.ema.europa.eu/en/documents/other/chmp-meeting-dates-2019-2020-2021_en.pdf
CHMP is for the European Union we also have applied to MHRA what is for the UK and it say within 60 days
Chester I read somewhere on the mhra website that’s its 60 days for a decision, I know they have submitted it to the ema as well do they do it at the end of the month , are they going to release both decisions at the same time or do it separately
Isn’t a decision meant to be within 60 days of a submission so 13th March deadline, As the 13th is next Saturday and i don’t recon they will be doing a rns on a Saturdays, so it should be released any time now
Rns
Wed, 24th Feb 2021 07:00
RNS Number : 0931Q
Diurnal Group PLC
24 February 2021
24 February 2021
Diurnal Group plc
("Diurnal" or the "Company")
Diurnal to present at Shares and AJ Bell Investor Evening Webinar
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will be presenting at the Shares and AJ Bell investor evening webinar on Tuesday 02 March 2021. The webinar will start at 18:00 GMT and investors can register to attend here: https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-020321.
Martin Whitaker, Chief Executive Officer of Diurnal, will be presenting an overview of the Company and will be available to take questions during the event.
For further information, please visit www.diurnal.co.uk or contact:
Diurnal Group plc
+44 (0)20 3727 1000
Martin Whitaker, Chief Executive Officer
Richard Bungay, Chief Financial Officer
Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker)
+44 (0)20 7886 2500
Corporate Finance: Freddy Crossley, Emma Earl
Corporate Broking: Rupert Dearden
FTI Consulting (Media and Investor Relations)
+44 (0)20 3727 1000
Simon Conway
Victoria Foster Mitchell
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-headquartered, European specialty pharma company developing hormone therapeutics for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency and hypogonadism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our com
I can’t see that doing much for the share price today as that is just an update to previously released RNS
Wasn’t all that information known already?
The deadline for approvals is the 13th March isn’t it ?? I do hope it comes sooner
Hopefully some good news today, I looked for Eton earnings report on one site it says between the 11th to the 17th March but on a other site it say it’s on the 29th March
Thursday, February 11 at 8:00 a.m. is the next Morning Media Update. What if your doctor could prescribe you a pill or give you a shot to treat your COVID symptoms? Dr. Mario Castro, pulmonologist and researcher, will join us to talk about new clinical trials testing three new outpatient treatments that may be game changers for COVID patients. They include an oral pill, an injection and a medication that can be inhaled through a nebulizer. Nearly all COVID patients are eligible for these new trials. There's no need to be older or high-risk to participate.